Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives

Elfadadny, Ahmed; El-Husseiny, Hussein M.; Abugomaa, Amira; Ragab, Rokaia F.; Mady, Eman A.; Aboubakr, Mohamed; Samir, Haney; Mandour, Ahmed S.; El‐Mleeh, Amany; El‐Far, Ali H.; El-Aziz, Ayman Hassan Abd; Elbadawy, Mohamed

doi:10.1007/s11356-021-15759-5

Cited by 32 publications

(13 citation statements)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-angiogenic effect of TOC is exerted by inhibiting the VEGFR and platelet-derived growth factor receptor, while its direct antitumor effect likely originates from inhibiting other tyrosine kinases. 13,39,40 Since blood vessels and angiogenesis are lacking in organoid culture models, the anti-angiogenic effect of TOC in our cMTC organoid line could not be assessed. 14 A possible explanation for the lack of effect of TOC on our cMTC organoid cells' viability could be an insufficient incubation time of the organoids with TOC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs

Scheemaeker

Inglebert

Daminet

et al. 2023

Vet Comparative Oncology

View full text Add to dashboard Cite

Organoid cultures could constitute a valuable in vitro model to explore new treatments for canine (c) medullary thyroid carcinoma (MTC). The study's objectives were to establish and characterize 3D organoid cultures of cMTC using histology and immunohistochemistry (IHC) and to evaluate the effect of antitumor drugs on organoids' viability.Five cMTC tissue samples were used to develop organoid cultures of which one organoid line, named cMTC N 2, could be passaged for an extended period. This cMTC N 2 organoid line was further compared to the primary tumour regarding morphology and IHC expression of thyroid transcription factor-1 (TTF-1), thyroglobulin, calcitonin, synaptophysin, vimentin, Ki-67, cyclooxygenase-2 (COX-2), P-glycoprotein and vascular endothelial growth factor (VEGF). Quality control of the cMTC N 2 organoid line was achieved by a single nucleotide polymorphism (SNP) array of the organoids, primary tumour and healthy blood cells of the same dog. The effect of carboplatin, meloxicam and toceranib phosphate (TOC) on cMTC N 2 organoids' viability was evaluated. The cMTC N 2 organoid line was cultured for 94 days and showed similar histological features with the primary tumour. Immunolabelling for TTF-1, thyroglobulin, calcitonin and VEGF was similar between the primary tumour and cMTC N 2 organoids. Compared to the primary tumour, organoids showed higher immunolabelling for vimentin and Ki-67, and lower immunolabelling for synaptophysin, COX-2 and P-glycoprotein. The SNP genotype was similar for each chromosome between healthy blood cells, primary tumour and cMTC N 2 organoids. Carboplatin, meloxicam and TOC had no effect on cMTC N 2 organoid cell viability within achievable in vivo concentration range. In conclusion, the cMTC N 2 organoid line is a promising first milestone towards an established in vitro organoid model to explore pathophysiology and new treatment modalities in cMTC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…9,10 Both, COX-2 inhibitors and TKIs, have also been shown to inhibit the expression and function of P-glycoprotein, which is an important cause of chemoresistance. [11][12][13] The development of an adequate in vitro model of cMTC could help elucidate the therapeutic value of COX-2 inhibitors and TKIs prior to clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs

Scheemaeker

Inglebert

Daminet

et al. 2023

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…Sometimes, chemotherapy is suggested after radiotherapy or surgery. Drugs that can bypass the BBB are commonly used as BT drugs, such as canmustine, temozolomide, and combinations of vincristine, lomustine, and procarbazine [ 20 ]. If the growth of the cancer cells is not retarded, then other treatment options are taken into consideration.…”

Section: A Background Search On Brain Cancermentioning

confidence: 99%

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach

et al. 2022

View full text Add to dashboard Cite

A brain tumor (BT) is a condition in which there is growth or uncontrolled development of the brain cells, which usually goes unrecognized or is diagnosed at the later stages. Since the mechanism behind BT is not clear, and the various physiological conditions are difficult to diagnose, the success rate of BT is not very high. This is the central issue faced during drug development and clinical trials with almost all types of neurodegenerative disorders. In the first part of this review, we focus on the concept of brain tumors, their barriers, and the types of delivery possible to target the brain cells. Although various treatment methods are available, they all have side effects or toxic effects. Hence, in the second part, a correlation was made between the use of resveratrol, a potent antioxidant, and its advantages for brain diseases. The relationship between brain disease and the blood–brain barrier, multi-drug resistance, and the use of nanomedicine for treating brain disorders is also mentioned. In short, a hypothetical concept is given with a background investigation into the use of combination therapy with resveratrol as an active ingredient, the possible drug delivery, and its formulation-based approach.

show abstract

“…Various cardiovascular cells have been obtained from iPSCs inside the cardiovascular system, and a recent study found that postnatal cardiac or dermal broblasts could be directly converted into cardiomyocyte-like cells (37,38). While personalized iPSCs or cardiomyocyte-like cells opened up a new avenue for autologous stem cell therapy, the risk of tumor development has arisen (39,40). Several sorts of SCs, including mesenchymal SCs (MSCs), embryonic SCs (ESCs), skeletal progenitor cells, hematopoietic SCs, and cardiac progenitor cells (CPCs), have presented a unique potential to develop functional CMs in the heart (34,37,(41)(42)(43).…”

Section: Scaffoldings and Cellsmentioning

confidence: 99%

Stimuli-responsive Hydrogels: Smart State of-the-art Platforms for Cardiac Tissue Engineering

El-Husseiny

Mady

El-Dakroury

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Biomedicine and tissue regeneration have made significant advancements recently, positively affecting the whole healthcare spectrum. This opened the way for them to develop their applications for revitalizing damaged tissues. Thus, their functionality will be restored. cardiac tissue engineering (CTE) using curative procedures that combine biomolecules, biomimetic scaffolds, and cells plays a critical part in this path. Stimuli-responsive hydrogels (SRHs) are excellent three-dimensional (3D) biomaterials for tissue engineering (TE) and various biomedical applications. They can mimic the intrinsic tissues' physicochemical, mechanical, and biological characteristics in a variety of ways. They also provide for 3D setup, adequate aqueous conditions, and the mechanical consistency required for cell development. Furthermore, they function as competent delivery platforms for various biomolecules. Many natural and synthetic polymers were used to fabricate these intelligent platforms with innovative enhanced features and specialized capabilities that are appropriate for CTE applications. In the present review, different strategies employed for CTE were outlined. The light was shed on the limitations of the use of conventional hydrogels in CTE. Moreover, diverse types of SRHs, their characteristics, assembly and exploitation for CTE were discussed. To summarize, recent development in the construction of SRHs increases their potential to operate as intelligent, sophisticated systems in the reconstruction of degenerated cardiac tissues.

show abstract

Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives

Cited by 32 publications

References 192 publications

Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs

Organoids of patient‐derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach

Stimuli-responsive Hydrogels: Smart State of-the-art Platforms for Cardiac Tissue Engineering

Contact Info

Product

Resources

About